Chimerix, Inc. (CMRX)

0,8999 +0,0089 (+1,00%) Alla chiusura: 04:00PM EDT

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919-806-1074
https://www.chimerix.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 72

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Michael T. Andriole M.B.A.	CEO, President & Director	592,95k	N/D	1973
Dr. Allen S. Melemed M.B.A., M.D.	Chief Medical Officer	605,29k	N/D	1964
Ms. Michelle LaSpaluto	Chief Financial Officer	N/D	N/D	1975
Mr. Thomas J. Riga	Chief Operating & Commercial Officer	N/D	N/D	1976
Mr. David Jakeman C.P.A.	Vice President of Accounting & Finance	N/D	N/D	1978
Dr. Joshua E. Allen Ph.D.	Chief Technology Officer	N/D	N/D	N/D
Dr. Michael A. Alrutz J.D., Ph.D.	Senior VP, General Counsel & Corporate Secretary	619,5k	N/D	1970
Dr. Roy W. Ware MBA, Ph.D.	Chief Manufacturing Technology Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di Chimerix, Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.